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http://dx.doi.org/10.1016/j.rmed.20
0954-6111/ª 2014 Elsevier Ltd. All rigBackground/purpose: The diagnosis of patients with pulmonary infiltrates and human immuno-
deficiency virus (HIV) infection remains a challenge. In current clinical practice the gold standard
for Pneumocystis jirovecii pneumonia (PCP) diagnosis remains the identification of the organism
in bronco alveolar lavage (BAL) using microscopy (e.g., silver stain). (1->3)-b -d-glucan (BG) is a
polysaccharide that is present within the cell wall of Pneumocystis and other fungi.
Methods: We analyzed serum and BAL lavage fluid from a cohort of 119 patients that did have
HIV, a diagnosis of pneumonia and underwent bronchoscopy (FOB) for diagnosis of PCP.
Results: The discriminative power of serum BG for the diagnosis of PCP in this group of patients
was very high. Using a cutoff of 300 pg/mL, the sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) were 91%, 92%, 89% and 93% respectively. A model for
ROCwith just serumBG (NZ 108) had anAUCof 0.95. Serumprocalcitonin (PCT) andBALBGwere
not as accurate for the diagnosis of PCP. For BAL BG using a cutoff of 783 pg/mL, the sensitivity,
specificity, positive predictive value (PPV) and negative predictive value (NPV) were 72%, 79%,
72% and 79% respectively. The differences between the medians for serum PCT between the
group with a without PCP did not reach statistical significance (pZ 0.6137).
Conclusion: The measurement of serum BG should be incorporated in the diagnostic work up of
HIV positive patients with dyspnea and infiltrates on chest X X-ray. Our study confirms the diag-
nostic value of serum BG previously reported by others but we add a cutoff value that we believe
is more accurate for patients with AIDS and suspicion of PCP.
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Diagnosis of Pneumocystis pneumonia 1689IntroductionThe diagnosis of patients with pulmonary infiltrates and
human immunodeficiency virus (HIV) infection remains a
frequent challenge [1]. Very often the only way to distin-
guish between Pneumocystis jirovecii pneumonia (PCP),
community-acquired pneumonia (CAP) and other entities is
by fiberoptic bronchoscopy (FOB), an invasive procedure
used to collect microbiologic samples. Many times patients
with PCP lack a productive cough and so sputum cannot be
obtained [2]. Sputum samples have a much lower sensitivity
for detection of PCP than bronchoalveolar lavage (BAL)
samples even with adequate induction. A meta-analysis [3]
found an overall sensitivity of 55.5% and specificity of 98.6%
for sputum induction; there was a difference in sensitivity
when immunofluorescence was used compared to cyto-
chemical stains (67.1 versus 43.1%). In current clinical
practice the gold standard for PCP diagnosis remains the
identification of the organism in BAL using microscopy
(e.g., silver stain) [4,5]. More recently, polymerase chain
reaction (PCR) has been used for diagnosis and quantifica-
tion of fungal load but may be limited by the detection of
colonization [1].
In recent years a promising serologic test for the
detection of invasive fungal infections has been estab-
lished. Serum measurement of (1->3)-b-D-glucan (BG) is
based on the level of this polysaccharide that is present
within the cell wall of Pneumocystis and other fungi [6].
The first description of elevated BG, both in serum and
BAL, of HIV positive patients with PCP was in 1996 [7]. Since
that time several studies have been reported. Using plasma
samples from a previous study, Sax et al. [8] found in 252
patients with HIV, that BG had a sensitivity of 92% and a
specificity of 65% for the diagnosis of PCP, using a cutoff
value of 80 pg/mL. In another study comparing 28 serum
samples of patients with HIV or hematological malignancy
vs. 28 control patients, the sensitivity and specificity of BG
for PCP were 100% and 96.4%, respectively [9]. A prospec-
tive study from Japan in immunocompromised patients
[10], using 40 BAL and 107 sputum samples of patients with
clinical suspicion of PCP, found a sensitivity and specificity
of 100% and 80% using a cutoff of 15 pg/mL of BG for the
diagnosis of definitive PCP (positive silver staining). The
values in probable PCP (negative silver staining but clinical
presentation compatible) were 76.2% and 73.3% at a cutoff
value of 6 pg/mL. In the Japanese study the kit used for BG
quantification was different from the kit currently
employed in the US. They did use the BG test WACO that
has a recommended cutoff value of 11 pg/mL and uses
different reagents for quantification, we did use for our
study the Fungitell assay, from Associates of Cape Cod,
Inc. that has a recommended cutoff value of 80 pg/mL. A
small prospective study from the Netherlands in HIV-
negative patients [11] also showed excellent diagnostic
accuracy of serum BG levels for the diagnosis of PCP. Using
the same samples of Sax et al. [8], but restricting the study
to patients with respiratory symptoms, Wood et al. [12]
were able to achieve a positive predictive value of 96.3%
using a cutoff of 80 pg/mL for the diagnosis of PCP. A recent
study from Portugal by Esteves et al. [13] employed serum
BG and serum lactate dehydrogenase for the diagnosis ofPCP in 100 HIV positive patients and 50 healthy blood do-
nors. They propose a cutoff of 400 pg/mL for serum BG as
optimal.
Several meta-analysis for the use of serum BG for the
diagnosis of invasive fungal infections have been published.
A recent one from He [14] included 4214 patients but did
focus mainly on invasive infections by Candida and Asper-
gillus. More recently Karageorgopoulos et al. [15] published
an excellent meta-analysis about the accuracy of BG for the
diagnosis of PCP. In their analysis they did include 14
studies, with 357 patients that had PCP and 1723 controls.
Their definition of PCP did include the detection of the
organism in BAL but also in sputum or by PCR. Most of those
patients were HIV-negative and did have another cause for
immunosupresion. Their overall sensitivity and specificity
was 94.7% and 86.3%. They suggest that a negative serum
BG could reasonably exclude PCP in patients with low or
moderate pretest probability for the disease.
BG was measured in BAL and serum in 109 immuno-
compromised patients with possible fungal infections in a
recent study from the Mayo Clinic [16]. Of 8 patients that
were diagnosed with PCP, 7 had positive serum and BAL
levels for BG. In those patients with PCP the median values
for BG in serum and BAL were 406 pg/mL and 500 pg/mL,
respectively. When BG has been measured in BAL [17,18]
the data appear to indicate that it does not add to the
diagnostic accuracy of serum levels alone. Of note, both
studies involved ventilator-associated pneumonia patients,
not HIV patients with acute pulmonary infiltrates. A more
recent paper [19] studying the utility of BAL BG testing in
invasive fungal infections did conclude that this measure-
ment has poor specificity and reproducibility. Of note the
measurement of BG in BAL is not validated for the
Fungitell assay. The lack of standardization in the BAL
technique could be in part a reason for this poor
reproducibility.
Another serologic marker, procalcitonin (PCT), has been
shown to be quite valuable and more specific than previous
markers for bacterial infections [20]. It is the peptide
precursor of the hormone calcitonin and is ubiquitously
produced in response to endotoxin and bacterial media-
tors. PCT levels strongly correlate with the extent and
severity of illness in several types of bacterial infections
[21]. More specifically, the use of procalcitonin in bacterial
pneumonia has proven to help with antibiotic guidance and
improve outcomes in several randomized controlled trials
[22,23].
PCT levels were assessed in a 2006 study from South
Africa [24] involving 266 patients admitted with a clinical
diagnosis of CAP. In 169 of those a microbiological diag-
nosis was made; 44 patients were found to have tubercu-
losis, 31 PCP, and 35 bacterial pneumonia. The mean PCT
levels for tuberculosis, PCP and bacterial pneumonia were
4.164 ng/mL (95% CI 1.749e6.579), 1.138 ng/mL (95% CI
.543e1.734) and 19.479 ng/mL (95% CI 8.021e30.938),
respectively. Moreover, a well-designed prospective study
from 2007 [25] included 107 consecutive patients with
various reasons for their immune-compromise state. In
that study, serum PCT had an area under the-curve of .746
(95% CI .602e.889) for the prediction of bacterial infec-
tion, defined as positive bacteriologic results in the BAL. In
1690 D. Salerno et al.this later study only 8 patients had HIV infection and
bacterial infection was established in 25% of the HIV
group.
The definition of Pneumocystis colonization has been
debated; it has been proposed based on the presence of
Pneumocystis microorganism or its DNA in the BAL of
asymptomatic individuals [26]. It is unclear if there is a
threshold of fungal load to cause disease. Recently, Costa
et al. [27], using stored serum and BAL samples from 63
patients, found a clear association between BAL fungal load
(measured by quantitative RT-PCR) and BG levels. They also
were able to demonstrate excellent sensitivity and speci-
ficity of BG for the diagnosis of PCP in their study
population.
The purpose of this study was to find the diagnostic ac-
curacy of the levels of serum BG, BAL BG and serum PCT in a
cohort of patients with HIV and respiratory symptoms who
were hospitalized and underwent FOB. The hypothesis was
that symptomatic HIV patients with BAL-proven PCP infec-
tion would have elevations in the level of BG, both in seraFigure 1 Patient-sampand BAL, and possibly lower levels of PCT when compared
to the PCP-negative patients.Materials and methods
Serum and bronchoalveolar fluid (BAL) samples from the
Louisiana State University (LSU) HIV Translational Research
Biorepository were utilized for this study. Those samples
were collected between 2007 and 2010 and frozen for
preservation; we did analyze them in 2013. The Bio-
repository banks excess material from clinically indicated
and acquired samples, along with a peripheral blood
collection, linked to a database of clinical variables. The
inclusion criteria were consecutive adult patients admitted
to the hospital with HIV and a diagnosis of pneumonia by a
physician who underwent FOB as part of their care. Those
patients who refused to give informed consent were
excluded. A clinical diagnosis of PCP required microbiologic
confirmation with methenamine silver or direct fluorescentles flow in the study.
Table 1 Baseline characteristics of study participants.
PCPþ (n Z 49) PCP (n Z 70) p
Age (Mean þ SD) 42.9 þ 7.6
(n Z 49)
45.0 þ 8.8
(n Z 65)
.1665
CD4 (Mean þ SD)
(Median, (IQR))
39.7 þ 60.9
16 (39)
(n Z 23)
131.3 þ 139.9
90 (153)
(n Z 44)
.0048
Male % (n) 69.4 (n Z 49) 68.6 (n Z 70) .9246
Using ART % (n) 8.2 (n Z 49) 40.0 (n Z 70) <.0001
Prior PCP % (n) 18.6 (n Z 43) 23.8 (n Z 63) .5232
Taking proph % (n) 11.1 (n Z 45) 38.2 (n Z 68) .0016
Oral candida % (n) 50.0 (n Z 48) 54.4 (n Z 68) .6393
In this table n represents in each cell the number of patients
with data available for analysis.
Chi-square test used to assess differences in frequencies.
t-test used to assess differences in age and log(CD4). Natural log
of CD4 was used for analysis because of skew in data, but results
were also verified with the Wilcoxon Rank Sum Test on un-
transformed values.
Table 2 Test performance for serum and BAL BG at
different cutoff levels.
Variables and
cutoffs
Sensitivity Specificity PPV NPV
Serum BG, pg/mL
80 .98
(.94, 1.0)
.39
(.27, .51)
.54
(.44, .65)
.96
(.88, 1.0)
300 .91
(.83, .99)
.92
(.85, .99)
.89
(.81, .98)
.93
(.87, 1.0)
490 .74
(.61, .87)
.95
(.90, 1.0)
.92
(.83, 1.0)
.83
(.74, .92)
BAL BG, pg/mL
241 .95
(.89, 1.0)
.39
(.26, .51)
.54
(.43, .65)
.92
(.81, 1.0)
783 .72
(.59, .86)
.79
(.68, .90)
.72
(.59, .86)
.79
(.68, .90)
2241 .12
(.02, .21)
.95
(.89, 1.0)
.63
(.29, .96)
.59
(.49, .69)
BG Z Betaglucan; PPV Z positive predictive value;
NPV Z negative predictive value.
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repository protocols were approved by the LSU Health Sci-
ences Center Institutional Review Board and all subjects
provided informed consent. The use of those samples for
the current study was approved by the Tulane University
Biomedical IRB in New Orleans, LA reference number 13-
420174E.
Commercially available assays for the measurement of
BG (Fungitell test, Associates of Cape Cod, Inc.) and PCT
(Vidas B.R.A.H.M.S test, bioMerieux, Inc.) were performed
on banked samples per the manufacturers’ standard pro-
tocols. The manufacturers’ thresholds for positive results
are 80 pg/mL and .5 ng/mL, respectively. The laboratory
technician performing the assay was unaware of the clinical
diagnoses of the patients.
The distributions of serum and BAL measures (serum BG,
serum PCT, and BAL BG) were positively skewed and
therefore not amenable to normalizing transformation, so
these data were summarized using medians and inter-
quartile ranges. Differences in concentrations were
assessed using the Wilcoxon Rank Sum test. Spearman
correlation coefficients (rho) were used to assess associa-
tions between the three measures. Receiver operating
characteristic (ROC) curves were computed using PCP þ or
PCP as the clinical diagnosis and BG (serum and BAL) and
PCT as the test variables. All analyses were conducted in
SAS version 9.3.
Results
Study population
The LSU HIV Translational Research Biorepository had 133
samples from consecutive patients, of those 119 had FOB
cytology results confirming PCP status and serum/BAL for
analysis. Among the 119 samples we were able to analyze
serum BG level in 108, BAL BG level in 100 and serum PCT in
108. Fig. 1 illustrates this. Baseline characteristics from the
cohort are presented in Table 1. We analyzed 49
PCP þ patients, the prevalence of PCP in this group was
41%. This cohort had profound HIV-related immunosup-
pression, was predominantly male and most of the patients
denied a prior history of PCP. Interestingly the description
of oral candidiasis was quite similar between the PCP and
PCP þ group. Comparing our PCP þ patients with the PCP
the first group had significantly lower CD4 counts and was
less likely to be using antiretroviral treatment or taking
prophylaxis for PCP.
Analysis of biomarkers
The discriminative power of serum BG for the diagnosis of
PCP in this group of patients was very high. Using a cutoff of
300 pg/mL, the sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) were 91%,
92%, 89% and 93% respectively. Table 2 illustrates how
serum BG and BAL BG performed at different cutoff levels.
When the PCP þ group was compared to the PCP group,
the differences in the values of serum and BAL BG in both
cases were statistically significant (p < .0001), as seen in
Figs. 2 and 3.A model for ROC curves using both serum and BAL BG was
created, with N Z 90 for serum BG, the area under the
curve (AUC) was .95, for BAL BG it was .81. In this case
serum BG was significantly better than BAL BG (p < .01). A
model with just serum BG (NZ 108) had an AUC of .95. On
the other hand, serum PCTwas not a significant predictor of
PCP (p Z .53), the AUC for serum PCT was .53. Fig. 4
demonstrate the ROC curves for serum and BAL BG levels.
Table 3 summarizes the results for our three biomarkers
when only patients with FOB cytology results were
included. A statistical difference (p < .0001) was achieved
when PCPþ was compared to PCP for serum and BAL BG
but not for serum PCT. The following results were obtained
when correlation between the biomarkers was assessed:
serum BG and BAL BG rho Z .49 p < .0001; serum BG and
serum PCT rho Z .09 p Z .3463.
Figure 2 Whisker and Box plot comparing serum BG between
PCP and PCPþ.
Figure 4 Receiver operating characteristic (ROC) curves for
serum and BAL BG.
1692 D. Salerno et al.Other fungal organisms
It is well known that BG is present in the cell wall of many
fungal organisms, so when BG is used for the diagnosis of a
specific fungal disease (PCP in our case) other fungal elements
might cause false positive results. In the 119 patients that we
analyzed 33 had fungal smear of culture positive for Candida
or yeast. Among those, using a cutoff for serum BG of 300 pg/
mL we just found one false positive case. In the group with
fungal smear of culture positive for Candida or yeast the false
positive ratewas 3% (1/33),whereas in the remaining patients
the false positive rate was 5% (4/86). Based on this it seems
like inour studythepresenceofCandidaoryeast in theBALdid
not cause a significant problem with false positives for serum
BG in the detection of PCP. Clinically, as seen in Table 1, oral
candidiasis was reported in around half of all our patients,
with no significant differences between the PCPþ and PCP
groups. It is important to notice that in general bronchoscopes
are introduced nasally, so if candida is really confined to the
mouth it might not contaminate the instrument.
Discussion
Our data support the hypothesis that serum BG has excel-
lent discriminatory power for the diagnosis of PCP inFigure 3 Whisker and Box plot comparing BAL BG between
PCP and PCPþ.patients with AIDS. Serum BG has the advantage of avoiding
invasive FOB, and based on our results was a better pre-
dictor of PCP than BAL BG. The measurement of serum BG
should be incorporated in the diagnostic work up of HIV
positive patients with dyspnea and infiltrates on chest X-
ray. It is unlikely for patients in this setting and BG values
below 300 pg/mL to have PCP. The clinician should use all
elements available (CD4 count, CXR findings, signs and
symptoms, use of ART, use of PCP prophylaxis) to make a
rational decision about the likelihood of infection in each
particular case. The recommended threshold value for the
Fungitell assay is 80 pg/mL. Based on the results from this
study, we propose that a threshold of 300 pg/mL for the
diagnosis of PCP in patients with AIDS may be more
appropriate.
On the contrary, serum PCT did not correlate with PCP
status in our study. Our initial hypothesis was that PCT,
employed as a marker of bacterial infection, might be low
in patients with an active fungal infection such as PCP. The
study from Nyamande et al. [24] showed significantly lower
PCT levels in patients with PCP compared to those withTable 3 Median values for BAL BG, serum BG and serum
PCT in patients PCPþ and PCP.
PCPþ (n Z 46) PCP (n Z 62) p
BAL BGa 1348 (634, 1939) 274 (118, 1939) <.0001
Serum BG 915 (479, 1267) 97 (61, 169) <.0001
Serum PCT .16 (.06, .44) .13 (.05, .52) .6137
Data are median (25th percentile, 75th percentile).
Differences assessed using the Wilcoxon Test.
a PCPþ n Z 43 and PCP n Z 57.
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tients [28] also showed the value of a low serum PCT in
differentiating pulmonary tuberculosis from bacterial
pneumonia, but did not include patients with PCP. A small
study of patients after lung transplantation [29] found a
relation between bronchial tree colonization by PCP and
increased serum PCT. In our study the serum PCT level did
not add information for the diagnosis of PCP. It is possible
that bacterial organisms in the alveolar space that were not
measured in our study affected our serum PCT results.
The diagnosis of patients with AIDS and pulmonary in-
filtrates on chest X-ray remains a clinical challenge. Recent
guidelines for diagnostic FOB from the British Thoracic So-
ciety [30] still define BAL as the gold standard for the
diagnosis of PCP. Its sensitivity before antibiotic adminis-
tration ranges between 90 and 98% [31,32], but after an-
tibiotics is reduced to around 64% [33]. Nevertheless, FOB is
not completely devoid of complications and adds cost and
duration to the patient’s hospital stay [34].
There are just 3 previous publications that did study BG
as a diagnostic tool for PCP exclusively in HIV patients.
Watanabe [35] did evaluate 111 patients, Sax [8] did eval-
uate 252 and Esteves [13] did analyze 100 HIV positives and
50 controls. None of them did study like we did BAL BG or
serum procalcitonin. Just Esteves did propose a new cut off
value for the test in this specific population, like we do. Is
also different the group from where the samples came in
those previous studies; in Sax it was patients with HIV and
acute opportunistic infections of all types, in Watanabe all
patients did have PCP and in Esteves there were healthy
controls and patients with HIV and respiratory symptoms.
Our study did include inpatients with HIV and diagnosis of
pneumonia, a group that more closely resembles the pop-
ulation where a clinician can use serum BG to help with the
diagnosis of PCP.
Another important aspect of this research is the fact
that patients with suspicion of pulmonary infections are
usually started on empiric antimicrobials well before
bronchoscopies are performed. Several studies have shown
that this practice impairs the diagnostic yield of BAL in
HIV þ patients with PCP, bacterial pneumonias and tuber-
culosis [33,36,37]. If appropriate serum biomarkers are
included in the early evaluation of HIV-associated pneu-
monia patients, the impact of this limitation could be
minimized.
One limitation to the application of BG testing in the
care of HIV-associated pneumonia is the “pan-fungal”
character of the BG test [9]. Positive results could be
related to other fungal infections (Candida, Aspergillus,
Histoplasma, etc.). While this is certainly relevant in a
broader population of immunosuppressed patients, within
the clinical context of HIV-related immunosuppression this
is likely less important. Other false positive BG results can
occur in patients on hemodialysis if cellulose membranes
are used, Gram negative bacteremia, severe mucositits,
exposure of samples to gauze, use of intravenous immu-
noglobulins as well perhaps the use of some antimicrobials
[12,38]. Some hospitals in the US that process BG in their
laboratories can give results in one day; therefore that
could impact clinical decision-making. Research to develop
a rapid in-house BG test is in progress. An interesting paper
from Austria [39] recently shown a validation for thedetection of candidemia using a rapid single sample in-
house BG test that provides results in less than one hour.
Another issue is the role of quantitative PCR (qPCR) for
the diagnosis of PCP [40]. There is still a debate about what
levels define colonization versus infection [41]. It is possible
that in certain settings qPCR for PCP might become the gold
standard for diagnosis, and then the correlation between
that marker and serum levels of BG will need further study.
A recent retrospective single-center study from France [27]
found a positive serum BG level, using a 80 pg/mL
threshold, in 25 of 26 samples that were BAL microscopy-
negative but qPCR positive for PCP. Another recent study
[42] in 46 patients concluded that a combination of qPCR
and serum BG (using a cutoff of 100 pg/mL) could differ-
entiate between PCP infection and colonization.
A final factor that could have influenced our results is
the timing of administration of antimicrobials for PCP.
Likely the majority of our patients were empirically treated
for PCP at the time of the FOB. Very few papers have
investigated the kinetics of serum BG after the initiation of
antifungal treatment [43,44]. However, it appears that the
decline of serum BG after treatment is slow and the value
should remain above the cut off for positivity for many
days. A prospective study with clearly defined timing of FOB
and initiation of treatment could overcome this limitation.
Another element that could have had some impact on
our results is the interaction during colonization of bacte-
rial and fungal organisms in the alveolar space. In a study by
Friaza et al. [45] the authors were able to show an antag-
onistic relationship between PCP and bacteria in a group of
patients with interstitial lung disease. The patients with
PCP colonization did have less bacterial microbiota di-
versity. The authors hypothesized that the fungal elements
create an inflammatory status that can interfere with
bacterial colonization or that increases its alveolar clear-
ance. This type of research has not yet been conducted in
patients with AIDS. Also it is important to notice that our
study was performed in an area of low tuberculosis preva-
lence, we do not know what impact will have in the bio-
markers that we measured using a group of patients from an
area with endemic tuberculosis.
One advantage of our study is the fact that our BG levels
were quantified even above 500 pg/mL. Some previous
studies have censored those values. Another important
aspect of our research is how well defined our population
was. Some previous reports have tested serum BG in a
broader mix of immunocompromised patients (HIV, hema-
tological malignancies, transplant recipients) and looked
for any type of invasive fungal infection [2,9,16,46]. Thus
our study design could translate into better application of
our results into clinical practice.
Our study is not suggesting dichotomizing the care of
patient with AIDS and suspicion of PCP based on results of
serum BG. The clinician should use all elements available
(CD4 count, CXR findings, signs and symptoms, use of ART,
use of PCP prophylaxis) to make a rational decision about
the likelihood of infection in each particular case. In the
future, using a larger prospective study it might be feasible
to create a clinical prediction rule for PCP in AIDS that
could incorporate serum BG and all the other elements
from laboratory, image and clinical data. It is also impor-
tant to mention that patients with HIV and PCP have higher
1694 D. Salerno et al.burden of pathogens than those with other types of
immunosuppression and PCP [15], and this might reflect in
the BG levels. So is quite possible that BG will be a better
diagnostic tool in the first group.
Conclusions
The measurement of serum BG should be incorporated into
the diagnostic work up of HIV positive patients with dyspnea
and infiltrates on chest X-ray. Using a cutoff of 300 pg/mL,
the sensitivity and specificity are above 90% and the NPV is
93% for the diagnosis of PCP. It is unlikely for patients in this
setting and BG values below our proposed cutoff have PCP.
The clinician should use all elements available (CD4 count,
CXR findings, signs and symptoms, use of ART, use of PCP
prophylaxis) to make a rational decision about the likelihood
of infection in each particular case. Our study confirms the
diagnostic value of serum BG previously reported by others
but we add a cutoff value that we believe is more accurate
for patients with AIDS and suspicion of PCP.
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